IDIS to distribute Genasense drugs ex-USA on named patient basis
UK distributor IDIS has signed an agreement to distribute two of USA-based Genta's oncology products, Ganite (gallium nitrate injection) and Genasense (oblimersen sodium) injection, on a named patient/compassionate use basis in all territories except the USA. Named patient distribution refers to the sale of a product to a specific health care professional for the treatment of an individual patient. Ganite is approved and marketed by Genta in the USA for the treatment of cancer-related hypercalcemia that is resistant to hydration. Genta is testing Genasense in ongoing clinical trials with other chemotherapy drugs in patients with melanoma and other diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze